PUBLISHER: Prescient & Strategic Intelligence | PRODUCT CODE: 1463764
PUBLISHER: Prescient & Strategic Intelligence | PRODUCT CODE: 1463764
Red Biotechnology Market Size and Share Report by Application, Product, End User - Global Industry Demand Forecast to 2030
Key Highlights
The red biotechnology market generated a value of USD 576.7 billion in 2023, and it will increase to USD 1,172.3 billion, advancing at more than 10.5% compound annual growth rate, by 2030.
The increasing need for it in clinical trials, drug discovery, carrier screening, and diagnostics, along with the rising incidence of genetic disorders aid the industry expansion.
Effective product development as well as genetic engineering relating to new drugs for treating life-threatening ailments are the key benefits of red biotechnology.
The increasing technological advancement rate in gene sequencing platforms, rising investment from private bodies and government for large-scale biotechnology plans, and substantial acceptance of red biotechnology across different applications like veterinary sciences, tissue engineering, and poultry farming, resulted in the industry expansion.
The increasing incidence of cancer and the surging use of this technology in cancer research & diagnostics are major drivers for this industry.
These technologies are employed for producing combination vaccines, including those that target Hepatitis A, Hepatitis B, polio, and diphtheria at once.
The rising count of R&D initiatives by major players, particularly in the area of stem cells, is a major trend in this industry.
Likewise, the pandemic of COVID-19 and a rising count of research studies discovering the use of this method for developing medicines, vaccines, and diagnostic tools assist industry expansion.
Key Insights
Biopharmaceutical production led the industry in 2023, with a 25.0% share, and it will further remain leading throughout this decade.
The increasing need for proteins, antibodies, antisense oligonucleotides, RNA, and DNA for diagnostic and therapeutic purposes is boosting the biopharmaceutical production category growth.
Gene therapy is likely to propel at the fastest compound annual growth rate in the years to come. The increasing incidence of genetic disorders as well as cancers is driving this category.
The human vaccines category led the industry in 2023, with a share of 30.0%, and it will continue this trend throughout this decade.
The human vaccines category growth is because of the increasing occurrence of infectious disease outbreaks and the rising prevalence of chronic ailments.
The biopharmaceutical industry was the largest contributor to the industry in 2023, with a 40.0% share, and it is likely to remain the largest during this decade.
The enhancing biopharmaceutical production infrastructure and R&D globally, to discover new molecule entities & vaccines against infectious ailments is driving the human vaccines category growth.
North America led the industry in 2023, with approximately 55% share, and it will further advance at a robust rate in the years to come.
The dominance of North America is because of the increasing incidence of rare, genetic, and chronic illnesses; the high technological improvement rate in the healthcare sector, and the rising number of R&D initiatives.
APAC is advancing at the fastest rate. This is because of the rising funding from both overseas and domestic biotech firms in this region and an enormous pool of patients with infectious and chronic ailments.
The red biotechnology industry is fragmented in nature, with the significant existence of large-scale companies.
These companies are involved in product launches, new product development, agreements, mergers, partnerships, and product approval to enhance their market presence.
Table of Contents
Chapter 1. Research Scope
- 1.1. Research Objectives
- 1.2. Market Definition
- 1.3. Analysis Period
- 1.4. Market Size Breakdown by Segments
- 1.4.1. Market size breakdown, by application
- 1.4.2. Market size breakdown, by product
- 1.4.3. Market size breakdown, by end user
- 1.4.4. Market size breakdown, by region
- 1.4.5. Market size breakdown, by country
- 1.5. Market Data Reporting Unit
- 1.5.1. Value
- 1.6. Key Stakeholders
Chapter 2. Research Methodology
- 2.1. Secondary Research
- 2.1.1. Paid
- 2.1.2. Unpaid
- 2.1.3. P&S Intelligence database
- 2.2. Primary Research
- 2.3. Market Size Estimation
- 2.4. Data Triangulation
- 2.5. Currency Conversion Rates
- 2.6. Assumptions for the Study
- 2.7. Notes and Caveats
Chapter 3. Executive Summary
Chapter 4. Market Indicators
Chapter 5. Industry Outlook
- 5.1. Market Dynamics
- 5.1.1. Trends
- 5.1.2. Drivers
- 5.1.3. Restraints/challenges
- 5.1.4. Impact analysis of drivers/restraints
- 5.2. Impact of COVID-19
- 5.3. Porter's Five Forces Analysis
- 5.3.1. Bargaining power of buyers
- 5.3.2. Bargaining power of suppliers
- 5.3.3. Threat of new entrants
- 5.3.4. Intensity of rivalry
- 5.3.5. Threat of substitutes
Chapter 6. Global Market
- 6.1. Overview
- 6.2. Market Revenue, by Application (2017-2030)
- 6.3. Market Revenue, by Product (2017-2030)
- 6.4. Market Revenue, by End User (2017-2030)
- 6.5. Market Revenue, by Region (2017-2030)
Chapter 7. North America Market
- 7.1. Overview
- 7.2. Market Revenue, by Application (2017-2030)
- 7.3. Market Revenue, by Product (2017-2030)
- 7.4. Market Revenue, by End User (2017-2030)
- 7.5. Market Revenue, by Country (2017-2030)
Chapter 8. Europe Market
- 8.1. Overview
- 8.2. Market Revenue, by Application (2017-2030)
- 8.3. Market Revenue, by Product (2017-2030)
- 8.4. Market Revenue, by End User (2017-2030)
- 8.5. Market Revenue, by Country (2017-2030)
Chapter 9. APAC Market
- 9.1. Overview
- 9.2. Market Revenue, by Application (2017-2030)
- 9.3. Market Revenue, by Product (2017-2030)
- 9.4. Market Revenue, by End User (2017-2030)
- 9.5. Market Revenue, by Country (2017-2030)
Chapter 10. LATAM Market
- 10.1. Overview
- 10.2. Market Revenue, by Application (2017-2030)
- 10.3. Market Revenue, by Product (2017-2030)
- 10.4. Market Revenue, by End User (2017-2030)
- 10.5. Market Revenue, by Country (2017-2030)
Chapter 11. MEA Market
- 11.1. Overview
- 11.2. Market Revenue, by Application (2017-2030)
- 11.3. Market Revenue, by Product (2017-2030)
- 11.4. Market Revenue, by End User (2017-2030)
- 11.5. Market Revenue, by Country (2017-2030)
Chapter 12. U.S. Market
- 12.1. Overview
- 12.2. Market Revenue, by Application (2017-2030)
- 12.3. Market Revenue, by Product (2017-2030)
- 12.4. Market Revenue, by End User (2017-2030)
Chapter 13. Canada Market
- 13.1. Overview
- 13.2. Market Revenue, by Application (2017-2030)
- 13.3. Market Revenue, by Product (2017-2030)
- 13.4. Market Revenue, by End User (2017-2030)
Chapter 14. Germany Market
- 14.1. Overview
- 14.2. Market Revenue, by Application (2017-2030)
- 14.3. Market Revenue, by Product (2017-2030)
- 14.4. Market Revenue, by End User (2017-2030)
Chapter 15. France Market
- 15.1. Overview
- 15.2. Market Revenue, by Application (2017-2030)
- 15.3. Market Revenue, by Product (2017-2030)
- 15.4. Market Revenue, by End User (2017-2030)
Chapter 16. U.K. Market
- 16.1. Overview
- 16.2. Market Revenue, by Application (2017-2030)
- 16.3. Market Revenue, by Product (2017-2030)
- 16.4. Market Revenue, by End User (2017-2030)
Chapter 17. Italy Market
- 17.1. Overview
- 17.2. Market Revenue, by Application (2017-2030)
- 17.3. Market Revenue, by Product (2017-2030)
- 17.4. Market Revenue, by End User (2017-2030)
Chapter 18. Spain Market
- 18.1. Overview
- 18.2. Market Revenue, by Application (2017-2030)
- 18.3. Market Revenue, by Product (2017-2030)
- 18.4. Market Revenue, by End User (2017-2030)
Chapter 19. Japan Market
- 19.1. Overview
- 19.2. Market Revenue, by Application (2017-2030)
- 19.3. Market Revenue, by Product (2017-2030)
- 19.4. Market Revenue, by End User (2017-2030)
Chapter 20. China Market
- 20.1. Overview
- 20.2. Market Revenue, by Application (2017-2030)
- 20.3. Market Revenue, by Product (2017-2030)
- 20.4. Market Revenue, by End User (2017-2030)
Chapter 21. India Market
- 21.1. Overview
- 21.2. Market Revenue, by Application (2017-2030)
- 21.3. Market Revenue, by Product (2017-2030)
- 21.4. Market Revenue, by End User (2017-2030)
Chapter 22. Australia Market
- 22.1. Overview
- 22.2. Market Revenue, by Application (2017-2030)
- 22.3. Market Revenue, by Product (2017-2030)
- 22.4. Market Revenue, by End User (2017-2030)
Chapter 23. South Korea Market
- 23.1. Overview
- 23.2. Market Revenue, by Application (2017-2030)
- 23.3. Market Revenue, by Product (2017-2030)
- 23.4. Market Revenue, by End User (2017-2030)
Chapter 24. Brazil Market
- 24.1. Overview
- 24.2. Market Revenue, by Application (2017-2030)
- 24.3. Market Revenue, by Product (2017-2030)
- 24.4. Market Revenue, by End User (2017-2030)
Chapter 25. Mexico Market
- 25.1. Overview
- 25.2. Market Revenue, by Application (2017-2030)
- 25.3. Market Revenue, by Product (2017-2030)
- 25.4. Market Revenue, by End User (2017-2030)
Chapter 26. Saudi Arabia Market
- 26.1. Overview
- 26.2. Market Revenue, by Application (2017-2030)
- 26.3. Market Revenue, by Product (2017-2030)
- 26.4. Market Revenue, by End User (2017-2030)
Chapter 27. South Africa Market
- 27.1. Overview
- 27.2. Market Revenue, by Application (2017-2030)
- 27.3. Market Revenue, by Product (2017-2030)
- 27.4. Market Revenue, by End User (2017-2030)
Chapter 28. U.A.E. Market
- 28.1. Overview
- 28.2. Market Revenue, by Application (2017-2030)
- 28.3. Market Revenue, by Product (2017-2030)
- 28.4. Market Revenue, by End User (2017-2030)
Chapter 29. Competitive Landscape
- 29.1. List of Market Players and their Offerings
- 29.2. Competitive Benchmarking of Key Players
- 29.3. Product Benchmarking of Key Players
- 29.4. Recent Strategic Developments
Chapter 30. Company Profiles
- 30.1. Pfizer Inc.
- 30.1.1. Business overview
- 30.1.2. Product and service offerings
- 30.1.3. Key financial summary
- 30.2. F. Hoffmann-La Roche Ltd.
- 30.2.1. Business overview
- 30.2.2. Product and service offerings
- 30.2.3. Key financial summary
- 30.3. Merck KGaA
- 30.3.1. Business overview
- 30.3.2. Product and service offerings
- 30.3.3. Key financial summary
- 30.4. AstraZeneca PLC
- 30.4.1. Business overview
- 30.4.2. Product and service offerings
- 30.4.3. Key financial summary
- 30.5. Takeda Pharmaceutical Company Limited
- 30.5.1. Business overview
- 30.5.2. Product and service offerings
- 30.5.3. Key financial summary
- 30.6. Amgen Inc.
- 30.6.1. Business overview
- 30.6.2. Product and service offerings
- 30.6.3. Key financial summary
- 30.7. Regeneron Pharmaceuticals Inc.
- 30.7.1. Business overview
- 30.7.2. Product and service offerings
- 30.7.3. Key financial summary
- 30.8. Gilead Sciences Inc.
- 30.8.1. Business overview
- 30.8.2. Product and service offerings
- 30.8.3. Key financial summary
- 30.9. Novartis AG
- 30.9.1. Business overview
- 30.9.2. Product and service offerings
- 30.9.3. Key financial summary
Chapter 31. Appendix
- 31.1. Abbreviations
- 31.2. Sources and References
- 31.3. Related Reports
